ROR1 and neoplasm: demonstrated the effectiveness of anti-ROR1 CAR-T cells in eliminating both NSCLC and TNBC cells, as shown in organoid tumor models (286) This evidence highlights the potential of anti-ROR1 CAR-T cell therapy as a promising and innovative strategy for treating NSCLC, providing new hope for patients in need of additional treatment options.